Skip to main content

Generics

  • Lupin receives FDA approval for generic Ultram ER tablets

    BALTIMORE — Lupin has received final approval from the Food and Drug Administration for its version of a drug designed to treat moderate to moderately severe chronic pain in adults who require around-the-clock treatment for an extended period of time.

    Lupin said that it received final approval for its abbreviated new drug application for tramadol hydrochloride extended-release tablets in the 100-mg, 200-mg and 300-mg strengths. The drug is a generic version of Ultram ER tablets, which is marketed by Johnson & Johnson subsidiary Ortho-McNeil-Janssen Pharmaceuticals.

  • Ragweed allergies high across nation; St. Louis med center offers steps toward relief

    ST. LOUIS — The St. Louis University Medical Center on Tuesday issued a step-by-step guide in tackling allergies, timely considering the recent uptick in ragweed allergies. According to Weather.com, weed allergens are particularly high right now across much of the continental United States.

    The guidelines:

  • Sagent names new CFO

    SCHAUMBURG, Ill. — Jonathon Singer has been appointed CFO of Sagent Pharmaceuticals, the generic drug maker said.

    Singer joins Sagent from Landauer, a leader in radiation sciences and services, where he served as SVP finance and CFO. Meanwhile, Sagent's current CFO, Ron Pauli, will be transitioned into a newly created role of chief business officer, where he will be responsible for product launch execution, product pipeline management and business development.

  • Dr. Reddy's to field Allegra-D store-brand equivalent

    HYDERABAD, India — Dr. Reddy’s Labs on Tuesday announced that it has launched its over-the-counter fexofenadine and pseudoephedrine extended-release tablets.

    Dr. Reddy’s will market the product, the equivalent to Allegra-D 24 Hour, under store-brand labels in the U.S. market, the company stated.

    Quarterly sales of Allegra-D totaled $13.5 million for the 12 weeks ended Aug. 7, according to SymphonyIRI Group tabulating sales across food, drug and mass (minus Walmart) outlets.

  • FDA approves Perrigo, Cobrek dermatitis drug

    ALLEGAN, Mich. — The Food and Drug Administration has approved a treatment for dermatitis made by Perrigo under a collaboration with Chicago-based Cobrek Pharmaceutical.

    The drug maker said Tuesday that the FDA approved ketoconazole foam in the 2% strength. The drug is a generic version of Stiefel Labs' Extina, a topical drug used to treat seborrheic dermatitis in patients ages 12 years and older with healthy immune systems.

    Extina has annual sales of about $10 million, according to Perrigo.

  • Federal court issues rulings in favor of Teva in MS drug case

    JERUSALEM — A federal court has acted in favor of Teva Pharmaceutical Industries in the drug maker's patent infringement case against several generic drug companies seeking to market versions of its multiple sclerosis drug.

  • Rx Response puts tool into play in communities impacted by Irene

    WASHINGTON — Rx Response late Monday announced it has activated its Pharmacy Reporting Status Tool to aid storm managers and people in communities affected by Hurricane Irene.

  • Report: Mylan temporarily banned from launching generic acne drug

    NEW YORK — Mylan will be banned temporarily from launching a generic drug for acne pending a federal court's decision whether or not to bar it, according to published reports.

X
This ad will auto-close in 10 seconds